Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Almirall, S.A., Ronda General Mitre 151, 08022 Barcelona, Spain
Klisyri 10 mg/g ointment.
| Pharmaceutical Form |
|---|
|
Ointment. White to off-white ointment. |
Each gram of ointment contains 10 mg of tirbanibulin.
Each sachet contains 2.5 mg of tirbanibulin in 250 mg ointment.
Excipients with known effects: Propylene glycol 890 mg/g ointment.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tirbanibulin |
Tirbanibulin disrupts microtubules by direct binding to tubulin, which induces cell cycle arrest and apoptotic death of proliferating cells, and is associated with disruption of Src tyrosine kinase signalling. |
| List of Excipients |
|---|
|
Propylene glycol |
Sachets with an inner layer of linear low-density polyethylene. Each sachet contains 250 mg of ointment.
Packs of 5 sachets.
Almirall, S.A., Ronda General Mitre 151, 08022 Barcelona, Spain
EU/1/21/1558/001
Date of first authorisation: 16 July 2021
| Drug | Countries | |
|---|---|---|
| KLISYRI | Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
